ICMR’s Pediatric Hydroxyurea Initiative: Strengthening the Fight Against Sickle Cell Disease

The Indian Council of Medical Research (ICMR) has recently invited Expressions of Interest (EoI) from pharmaceutical companies to develop an oral liquid formulation of hydroxyurea. This drug is the primary treatment for Sickle Cell Disease (SCD), a genetic blood disorder that causes red blood cells to become misshapen and break down, leading to severe health complications. India carries the second-highest global burden of Sickle Cell Disease, with a particularly high prevalence among tribal communities. The disease leads to chronic anemia, painful vaso-occlusive crises, and potential organ damage. While hydroxyurea is effective in reducing the frequency of these painful episodes and the need for blood transfusions, its current availability in India is primarily in the form of capsules and tablets, which are not ideal for all age groups. The shift toward a liquid formulation is a strategic public health intervention. Pediatric patients often struggle with swallowing solid dosage forms. Furthermore, liquid formulations allow for more precise, weight-based dosing, which is essential for children whose requirements change as they grow. By making the medication easier to administer, the ICMR aims to improve treatment adherence and long-term health outcomes for the youngest patients.